In recent decades, advances in kidney disease treatment, including the introduction of novel reno-protective agents such as SGLT2 and GLP-1 inhibitors, have the potential to reduce overall disease burden and address racial disparities in kidney disease [33]. Here, SLC5A2 is linked to kidney disorder.